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Abstract
Background: To compare volumetric-modulated arc therapy plans with conventional radiation therapy (3D-CRT)
plans in pancreatic and bile duct cancers, especially for bilateral kidney preservation.
Methods: A dosimetric analysis was performed in 21 patients who had undergone radiotherapy for pancreatic or
bile duct carcinoma at our institution. We compared 4-field 3D-CRT and 2 arcs RapidArc (RA) plans. The treatment
plan was designed to deliver a dose of 50.4 Gy to the planning target volume (PTV) based on the gross disease in
a 1.8 Gy daily fraction, 5 days a week. Planning objectives were 95% of the PTV receiving 95% of the prescribed
dose and no more than 2% of the PTV receiving more than 107%. Dose-volume histograms (DVH) for the target
volume and the organs at risk (right and left kidneys, bowel tract, liver and healthy tissue) were compared. Monitor
units and delivery treatment time were also reported.
Results: All plans achieved objectives, with 95% of the PTV receiving ≥ 95% of the dose (D95% for 3D-CRT = 48.9
Gy and for RA = 48.6 Gy). RapidArc was shown to be superior to 3D-CRT in terms of organ at risk sparing except
for contralateral kidney: for bowel tract, the mean dose was reduced by RA compared to 3D-CRT (16.7 vs 20.8 Gy,
p = 0.0001). Similar result was observed for homolateral kidney (mean dose of 4.7 Gy for RA vs 12.6 Gy for 3D-CRT,
p < 0.0001), but 3D-CRT significantly reduced controlateral kidney dose with a mean dose of 1.8 Gy vs 3.9 Gy, p <
0.0007. Compared to 3D-CRT, mean MUs for each fraction was significantly increased with RapidArc: 207 vs 589, (p
< 0.0001) but the treatment time was not significantly different (2 and 2.66 minutes, p = ns).
Conclusion: RapidArc allows significant dose reduction, in particular for homolateral kidney and bowel, while
maintaining target coverage. This would have a promising impact on reducing toxicities.
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Background
Over the last decades, progress in treating pancreatic
cancer has remained modest, and the disease is still
associated with very poor prognosis regardless of stage.
Although there is currently no clear standard therapy,
chemotherapy (CT) alone or radiochemotherapy (RCT)
are two treatment options available for patients with
non metastatic locally advanced pancreatic cancer. Two
systematic reviews have shown no difference between
both treatment modalities in terms of overall survival,
but an increased toxicity with RCT [1,2]. Lack of benefit
for RCT can be explained by the low compliance related
to acute toxicity. In a recently published phase 3 trial
comparing intensive induction chemoradiation followed
by gemcitabine to gemcitabine alone, Barhoumi et al.
reported that only 42% of patients were able to receive
75% of the planned chemoradiation schedule (60 Gy, 2
Gy/fraction and concomitant infusion of 5-fluorouracil
and cisplatin) whereas 73% of patients were given 75%
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of the treatment of gemcitabine alone (1,000 mg/m2
weekly) [3]. Interestingly, the administration of induc-
tion chemotherapy before RCT has been shown to be a
promising strategy for selected patients with non pro-
gressive disease, which may help to define the subset of
patients likely to benefit from RCT while sparing those
with rapidly progressive disease from potentially toxic
radiotherapy [4]. In the case of resectable pancreatic
cancer, it is now well established that RCT should be
only considered in the adjuvant setting after insufficient
pancreatic resection [5], whereas for bile duct malignan-
cies, radiotherapy (RT) is likely to prolong survival in
case of locally advanced disease as well as after R1
resection [6].
The occurrence of toxicity is clearly associated with
the use of old RT techniques and the delineation of
important target volumes. Besides, recent data regarding
the treatment of pancreatic disease are in favor of RCT
without prophylactic irradiation of peripancreatic lymph
nodes since the use of small radiation fields seems to
provide similar local recurrence rates and lower gastro-
intestinal (GI) toxicity [7,8]. The goal of modern radio-
therapy such as the intensity modulated radiation
therapy (IMRT) or the volumetric-modulated arc ther-
apy (VMAT) is to insure full delivery of the prescribed
dose, even to allow dose escalation while reducing doses
to surrounding critical organs (small bowel, kidneys,
spinal cord). A few studies investigated IMRT for pan-
creatic cancers and showed a statistically significant
improvement over three dimensional conformal radio-
therapy (3D-CRT) in lowering dose to the liver, stomach
and bowel [9-12]. Therefore, advances in RT delivery
with IMRT suggest a tolerability advantage including a
lower incidence of acute toxicity [13,14]. In addition to
a favorable toxicity profile, the local control is not com-
promised with IMRT [15].
Volumetric-modulated arc therapy (RapidArc) is a
new form of IMRT optimization combining one gantry
rotation and the capability to vary dose-rate, gantry
speed and dynamic multi leaf collimator (MLC) [16].
Details of the RapidArc process and specific quality
assurance procedures have been described in several
publications [16,17]. The VMAT approach has a num-
ber of potential advantages compared to IMRT by sig-
nificantly reducing the treatment time and the number
of monitor units (MU), and improving normal tissue
sparing while keeping the adequate target coverage
[18-20]. In a trial comparing VMAT and IMRT for pan-
creatic cancers, VMAT was shown to provide superior
conformity indices to the target and to reduce the dose
in organs at risk (OAR) volumes with a shorter delivery
time [21].
The purpose of the present study was to perform a
comparative dosimetric analysis of RapidArc and 3D-
CRT techniques in the treatment of pancreatic and bile
duct malignancies with a special focus on the preserva-
tion of bowel and bilateral kidney function.
Methods and materials
Treatment plans
Treatment plans from 21 consecutive patients previously
treated in our institution for pancreatic cancer (n = 17)
or cholangiocarcinoma (n = 4) were used for this study.
Among patients with pancreatic cancer, 14 patients had
undergone radiation therapy for unresectable locally
advanced disease, 2 for local recurrence after curative
resection and 1 for adjuvant treatment due to insuffi-
cient surgical resection. Cholangiocarcinoma treatment
plans were obtained from 2 patients with locally
advanced disease, one patient with local recurrence and
one having received adjuvant therapy.
The gross tumor volume (GTV) was determined by
CT-scan and/or position emission tomography (PET)
scan, and was defined as the tumor and enlarged regio-
nal lymph nodes. Clinical target volume (CTV) consisted
of microscopic extensions around the GTV, as well as
the anastomotic site and surgical clips in case of adju-
vant treatment. When a 4D-CT scan was used, an inter-
nal target volume (ITV) was created to account for
respiratory motion in 3 dimensions. The planning target
volume (PTV) was a 0.5-1 cm expansion of the CTV
(and internal target volume (ITV) if existing). The OAR
included bowel, spinal cord, liver, left and right kidneys,
and the healthy tissue was defined as the body covered
by the CT scan minus the PTV. The treatment plan was
designed to deliver a total dose of 50.4 Gy to the PTV
in 1.8 Gy daily fractions, 5 days a week.
Simulation and optimization
For all patients, simulation was performed on CT scan
(RT 16 PRO CT Simulator, General Electrics Systems,
Cleveland, OH) with 2.5 mm thick slices. Patients were
simulated in the supine position. Four-field 3D-CRT
and RapidArc optimization was performed using the
treatment planning system Eclipse version 8.9 (Helios,
Varian, Palo Alto, CA). Calculation was performed with
AAA algorithm, and grid of 2.5 mm.
For 3D-CRT, we selected beam orientation in a way to
preserve one kidney in beam eye view (4 beams: anterior
(0°), posterior (180°), right (270°) and left (90°). We
modified right and left beams in order to avoid totally
one kidney at least. Treatment plans were generated
using 18 MV photon energy. An 8-mm margin was
added to PTV for MLC. The maximum dose rate of 200
MU per minute was selected.
For RapidArc plans, progressive resolution algorithm
PRO 8.9.08 was used with 6 MV energy. We used 18
MV for 3D-RT plans to reduce peripheral dose deposit
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for this deep PTV. With RA, intrinsic value of energy
beam is less important due to the number of beams
used. The maximum dose rate of 400 MU per minute
was selected. Two 360° coplanar arcs sharing the same
isocenter and optimized simultaneously were used.
These two arcs were delivered with opposite rotation
(clock and counter-clock) and so minimize the off-treat-
ment time between the two beams to about 25 seconds.
The field size for both arcs was determined by the auto-
matic tool from Eclipse to encompass the PTV, rotation
of the collimator was 45° for the first arc, and 315° for
the second arc. Collimator was always rotated to a value
different from zero in order to avoid tongue and groove
effect. Plans were normalized to cover at least 95% of
the PTV with ≥ 95% of the prescribed dose. No more
than 2% of the PTV was allowed to receive more than
107% of the prescribed dose. Vx is used throughout the
analysis to represent the volume receiving “x” Gy or
greater dose.
Statistical methodology and main objective
Dose-volume histograms (DVH) for the target volume
and the OAR (right and left kidneys, bowel tract, liver
and healthy tissue) were analyzed. The mean and maxi-
mum (defined as the maximum dose given to 1% of
volume in order to avoid single voxel dose overesti-
mates) doses to the PTV were measured. The volume
receiving more than 95% of the prescribed dose (V95),
and the average doses to OAR (small bowel, homolat-
eral, contralateral and both kidneys, spinal cord, liver)
were also recorded. A non-parametric Wilcoxon
matched pair test was used for comparison between the
values of 3D-CRT and RA for OAR and PTV. A two-
tailed p value < 0.05 was used to indicate statistical
significance.
Our study aimed to determine whether the 3D-CRT
and RapidArc plans allow the treatment to be delivered
at the prescribed dose for PTV, without requiring PTV
volume adjustment or dose reduction. The main goal
was to evaluate the efficiency of both techniques to
obtain the lowest dose to the OAR with respect to ideal
dose constraints, namely for each kidney:
V10 = 0 Gy, Dmean < 5 Gy, for the spinal cord a
maximum dose of 40 Gy, and minimized doses for liver
and bowel. Our research that is reported in the manu-
script has been performed with the approval of our local
ethical committee but was carried out only on dosi-
metric application and not on humans.
Results
PTV
The mean PTV was 265 ± 100 cm3 (range: 82.4-537.7
cm3). Figure 1 shows PTV volumes for all the patients.
RA and 3D-CRT plans had excellent coverage of the
PTV with at least 95% of the PTV receiving ≥ 95% of
the prescribed dose. The DVH for PTV are shown in
Figure 2 and results are reported in table 1. Values for
the homogeneity index (HI), defined as the (D2-D98)/
mean dose ratio, were 0.048 and 0.081 for 3D-CRT and
RA, respectively.
Organs at risk
Table 2 details numerical findings for the kidneys, and
table 3 reports the results for the other OAR. RA
 
Figure 1 PTV volume.
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significantly decreased mean dose (4.7 ± 1.9 vs. 12.6 ±
8.3 Gy), V20 (0.8 ± 2.9 vs. 31.8 ± 24%), V10 (6.4 ± 11.8
vs. 43.6 ± 25.8%), and V5 (40.0 ± 21.5 vs. 52.2 ± 27%)
for the homolateral kidney. Conversely, we observed
lower mean doses (1.8 ± 2.1 Gy vs. 3.9 ± 0.9 Gy) and
V5 values (6.7 ± 11.4 vs. 34.0 ± 18.5%, p < 0.05) for the
contralateral kidney with 3D-CRT (Figure 3). The mean
dose, V30 and V40 values for bowel were significantly
lower with RA compared with 3D-CRT (mean dose:
16.7 ± 6.2 vs. 20.8 ± 6.3 Gy, p = 0.0001, V30 (cc): 135.4
± 91.3 vs. 180.6 ± 116.6, p = 0.023, V40 (cc): 39.0 ±
42.4 vs. 79.0 ± 72.5, p < 0.0001) (Figure 4). The mean
dose (Gy) (10.5 ± 5.4 vs. 12.5 ± 6.3, p < 0.0001) and
V30 (%) (8.2 ± 8.5 vs. 11.7 ± 10.8, p: 0.0019) values for
liver were significantly lower with RA as compared with
3D-CRT, respectively. The maximum dose allowed to
spinal cord was 40 Gy, and this constraint was achieved
in 100% of the plans, regardless of the technique (25.5 ±
5.4 for 3D-CRT and 29.6 ± 8.7 for RA) (Figure 5). Dose-
volume histograms for healthy tissue (body-PTV) are
shown in Figure 6.
Representative dose distributions for both techniques
are shown in Figure 7.
Figure 2 Average dose-volume histograms (DVH) for the right
and left kidney, achieved with RA (solid lines) and 3D-CRT
(dashed lines).
Table 1 Comparison of PTV between RapidArc (RA) and conventional radiation therapy (3D-CRT) plans
3D-CRT RA
PTV mean SD Range mean SD Range p-value
Mean dose (Gy) 50.2 0.6 49.2-53.3 50.5 0.9 48.7-51.1 0.5621
D95 (Gy) 48.9 0.8 47.0-49.2 48.6 0.5 46.0-50.0 0.0159
D98 (Gy) 48.1 2.4 38.0-49.4 47.4 2.1 38.6-48.5 0.0007
D2 (Gy) 51.2 0.7 49.5-52.3 52.3 1.4 50.1-57.0 0.0071
Table 2 Comparison of renal doses between RapidArc (RA) and conventional radiation therapy (3D-CRT) plans.
3D-CRT RA
mean SD Range mean SD Range p-value
Homolateral kidney
Mean dose (Gy) 12.6 8.3 1.1-31.5 4.7 1.9 2.9-10.2 < 0.0001
V5 (%) 52.2 27.0 4.1-95.9 40.0 21.5 4.3-93.0 0.0033
V10 (%) 43.6 25.8 1.89-90.1 6.4 11.8 0-37.0 < 0.0001
V20 (%) 31.8 24.0 0.0-80.7 0.8 2.9 0.0-13.7 < 0.0001
Controlateral kidney
Mean dose (Gy) 1.8 2.1 0.2-8.7 3.9 0.9 1.8-5.6 0.0007
V5 (%) 6.7 11.4 0.0-41.38 34.0 18.5 3.5-80.5 < 0.0001
V10 (%) 3.9 8.1 0.0-30.92 2.2 8.1 0.0-37.3 0.4131
V20 (%) 2.1 4.9 0.0-19.9 0.0 0.0 0.0-0.0 0.1641
Both kidneys
Mean dose (Gy) 7.1 4.2 0.9-16 4.3 1.1 2.4-6.9 0.0014
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Monitor unit and delivery time
The mean number of MU was significantly lower for
3D-CRT: 208.3 ± 13.5 (min-max: 187-241) vs. 569.6 ±
92.8 (min-max: 367-716) (p < 0.0001), and delivery
treatment times (defined as the start to the end of the
irradiation) were 2 and 2.66 minutes, respectively (NS).
Discussion
The treatment of pancreatic cancer remains a major
clinical challenge. Only 20% of patients are considered
eligible for curative surgical resection, whereas radio-
therapy given as definitive treatment or adjuvant treat-
ment is a subject of controversy, essentially because of
radiation-induced toxicity. It is now generally accepted
that RA technology offers the potential to deliver better
conformal radiation dose with less toxicity as compared
with 3D-RT [9-15]. In the present study, we chose to
directly compare 3D-CRT with RA without testing
IMRT for two main reasons. Firstly, several studies have
already demonstrated benefit of IMRT over 3D-CRT
[13-15], and advantage of VMAT over IMRT in terms
of conformity and OAR dose reduction [21]. Secondly,
in our institution, the RA technique has been imple-
mented as a standard of care for many tumor sites, and
is preferred to IMRT because of shorter delivery time.
That choice has direct impact on daily practice by
improving patient comfort and reducing intrafraction
changes in patient position [20].
Table 3 Comparison of doses to organs at risk between RapidArc (RA) and conventional radiation therapy (3D-CRT)
plans
3D-CRT RapidArc
mean SD Range mean SD Range p-value
Bowell
Mean dose (Gy) 20.8 6.3 10.7-36.4 16.7 6.2 6.5-35.8 0.0001
V30 (cc) 180.6 116.6 12.8-486.2 135.4 91.3 0.0-308.6 0.023
V40 (cc) 79.0 72.5 0.5-201.2 39 42.4 0.0-148.7 < 0.0001
Liver
Mean dose (Gy) 12.5 6.3 2.8-25.0 10.5 5.4 2.3-23.1 < 0.0001
V30 (%) 11.7 10.8 0.0-35.1 8.2 8.5 0.0-28.7 0.0019
Spinal cord
Dmax (Gy) 25.6 5.4 10.0-28.8 29.6 8.7 9.3-37.2 0.0121
Figure 3 Average dose-volume histograms (DVH) for the
bowel, achieved with RA (solid lines) and 3D-CRT (dashed
lines).
Figure 4 Average dose-volume histograms (DVH) for the liver
and spinal cord, achieved with RA (solid lines) and 3D-CRT
(dashed lines).
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In this dosimetric analysis, particular emphasis was
placed on improving kidney sparing according to the
Quantec constraints [22]. Much has changed since the
papers by Emami et al., and later Cassady et al., suggest-
ing that total doses of 18-23 Gy and 28 Gy in 0.5-1.25
Gy/fraction may be associated with a 5% and 50% risk
of injury at 5 years, respectively [23,24]. Nowadays, con-
ventional treatments are delivered in 2 Gy daily frac-
tions, so we need to take caution with these first
published cut-offs. According to current recommenda-
tions for partial bilateral kidney radiotherapy, the mean
dose should be lower than 15-18 Gy and the V20 lower
than 32%, but substantial uncertainty still remains
because few published data are available. Moreover,
study follow-up periods are usually too short to draw
any clear conclusions [22]. RT-induced kidney injury is
generally subclinical. Signs and symptoms including
arterial hypertension and renal failure usually do not
develop until late and their incidence is often underesti-
mated because of a long latency period and the short-
life expectancy of the majority of the patients suffering
from pancreas cancer. Conventional 3D-CRT allows
total preservation of contralateral kidney, but has a det-
rimental effect on homolateral kidney. In the new era of
arctherapy, it is crucial to minimize as much as possible
the dose to both kidneys for bilateral preservation. For
Figure 5 Average dose-volume histograms (DVH) for the




Figure 6 Average dose-volume histograms (DVH) for the




Figure 7 Poverage of PTV by 95% isodose for A: 3D-RT and B:
Rapidarc.
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this reason, we decided to set strong dose constraints
for each kidney, i.e. a V10 of 0 Gy and a mean dose < 5
Gy with a successful achievement. In the comparative
planning study of VMAT and IMRT conducted by
Eppinga et al. in a series of 10 patients with locally
advanced pancreatic cancer, doses to the left kidney
were significantly reduced with VMAT (V15 of 7.2%
and V20 of 2.4%), whereas right kidney sparing was
similar with both techniques (V15 of 20.4% and V20 of
9.9% with VMAT). The mean doses delivered to the left
and right kidneys were 8.8 and 10.9 Gy, respectively
[21].
Our PTV’s volumes were smaller. This difference may
explain for a part the improvement of OAR sparing. In
our present study, the delineation of CTV/PTV corre-
sponds to the new guidelines (manuscript accepted for
publication in the Int J Radiat Oncol Biol Phys).
It is unclear if any of these dose and volume para-
meters could be sufficient to preserve renal function,
and the lack of clinical outcome data makes challenging
the interpretation of any results. This is the reason why
the kidney function of patients requiring abdominal
radiotherapy and treated by RA in our institution is now
routinely evaluated at baseline. A dimercaptosuccinic
acid (DMSA) scintigraphy is performed before and at
the end of treatment, and blood tests are carried out
during the follow-up period. Since early changes in
renal flow are correlated with an increased toxicity, this
management offers the possibility to accurately evaluate
radiation-associated kidney injury.
Our study demonstrated that kidney sparing can be
achieved without compromising the bowel function.
Improvements in decreasing dose to the bowel are
therefore essential because GI toxicity is the most com-
mon acute side effect. Devisetty et al. showed a signifi-
cant higher acute GI toxicity for V30 > 450 cm3 than
for V30 ≤ 450 cm3 (33% vs. 8%, p = 0.003, respectively)
[25]. Recommendations for V45 < 195 cm3 when perito-
neal cavity was delineated were reported by Kavanagh et
al. [26,27]. We delineated the bowel as the peritoneal
cavity, and obtained a V30 < 200 cm3 and a V40 < 55
cm3 with RA, which is very promising for reducing
acute digestive toxicity. Dosimetric data with respect to
the liver complied with the Quantec recommendations
(i.e. mean dose < 30-32 Gy) for both techniques with
reported mean doses of 11.0 Gy and 9.7 Gy with 3D-
CRT and RA, respectively [27].
Despite these positive results, the IMRT/RA techni-
ques raise concerns about the increased number of MU
required, and the low-dose radiation delivered to healthy
tissue compared with 3D-RT treatment leading to a
potential increase of the risk of secondary malignancies
[28,29]. In this study, we noted superiority of 3D-CRT
over RA for doses inferior to 15 Gy, but for “middle
doses” (> 15Gy) healthy tissue doses were decreased by
RA. The real impact and the dose level potentially incri-
minated in the risk of developing a second cancer are
still unclear.
Conclusion
The RA technique results in better OAR sparing than
3D-CRT for pancreatic and bile duct malignancies, espe-
cially for small bowel and kidney preservation, while
covering target volume, making the rationale for use of
radiotherapy in these diseases more solid and less con-
troversial. These improvements have led us to imple-
ment rapidly this technique into the clinic as a standard
of care for pancreatic and bile duct cancers and after 4
to 6 cycles of chemotherapy.
Conflict of interest notification
The authors declare that they have no competing
interests.
Authors’ contributions
SV, PF conceived the study, collected data, and drafted the manuscript. NA,
JBD, OR and DA participated in coordination and helped to draft the
manuscript. DA provided mentorship and edited the manuscript. All authors
have read and approved the final manuscript.
Received: 5 August 2011 Accepted: 31 October 2011
Published: 31 October 2011
References
1. Sultana A, Sultana A, Tudur Smith C, Cunningham D, Starling N, Tait D,
Neoptolemos JP, Ghaneh P: Systematic review, including meta-analyses,
on the management of locally advanced pancreatic cancer using
radiation/combined modality therapy. Br J Cancer 2007, 96:1183-1190.
2. Yip D, Karapetis C, Strickland A, Steer CB, Goldstein D: Chemotherapy and
radiotherapy for inoperable advanced pancreatic cancer. Cochrane
Database Syst Rev 2006, 3:CD002093.
3. Barhoumi M, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouché O,
Bosset JF, Aparicio T, Mineur L, Azzedine A, Hammel P, Butel J,
Stremsdoerfer N, Maingon P, Bedenne L, Chauffert B: Locally advanced
unresectable pancreatic cancer: Induction chemoradiotherapy followed
by maintenance gemcitabine versus gemcitabine alone: Definitive
results of the 2000-2001 FFCD/SFRO phase III trial. Cancer Radiother 2011,
15:182-191.
4. Huguet F, Girard N, Guerche CS, Hennequin C, Mornex F, Azria D:
Chemoradiotherapy in the management of locally advanced pancreatic
carcinoma: a qualitative systematic review. J Clin Oncol 2009,
27:2269-2277.
5. Klautke G, Brunner TB: Radiotherapy in pancreatic cancer. Strahlenther
Onkol 2008, 184:557-564.
6. Brunner TB, Eccles CL: Radiotherapy and chemotherapy as therapeutic
strategies in extrahepatic biliary duct carcinoma. Strahlenther Onkol 2010,
186:672-680.
7. Goldstein D, Van Hazel G, Walpole E, Underhill C, Kotasek D, Michael M,
Shapiro J, Davies T, Reece W, Harvey J, et al: Gemcitabine with a specific
conformal 3D 5FU radiochemotherapy technique is safe and effective in
the definitive management of locally advanced pancreatic cancer. Br J
Cancer 2007, 97:464-471.
8. Murphy JD, Adusumilli S, Griffith KA, Ray ME, Zalupski MM, Lawrence TS,
Ben-Josef E: Full-dose gemcitabine and concurrent radiotherapy for
unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2007,
68:801-808.
9. Brown MW, Ning H, Arora B, Albert PS, Poggi M, Camphausen K, Citrin D: A
dosimetric analysis of dose escalation using two intensity-modulated
Vieillot et al. Radiation Oncology 2011, 6:147
http://www.ro-journal.com/content/6/1/147
Page 7 of 8
radiation therapy techniques in locally advanced pancreatic carcinoma.
Int J Radiat Oncol Biol Phys 2006, 65:274-283.
10. Landry JC, Yang GY, Ting JY, Staley CA, Torres W, Esiashvili N, Davis LW:
Treatment of pancreatic cancer tumors with intensity-modulated
radiation therapy (IMRT) using the volume at risk approach (VARA):
employing dose-volume histogram (DVH) and normal tissue
complication probability (NTCP) to evaluate small bowel toxicity. Med
Dosim 2002, 27:121-129.
11. Poppe MM, Narra V, Yue NJ, Zhou J, Nelson C, Jabbour SK: A Comparison
of Helical Intensity-Modulated Radiotherapy, Intensity-Modulated
Radiotherapy, and 3D-Conformal Radiation Therapy for Pancreatic
Cancer. Med Dosim 2010.
12. Van der Geld YG, van Triest B, Verbakel WF, van Sörnsen de Koste JR,
Senan S, Slotman BJ, Lagerwaard FJ: Evaluation of four-dimensional
computed tomography-based intensity-modulated and respiratory-gated
radiotherapy techniques for pancreatic carcinoma. Int J Radiat Oncol Biol
Phys 2008, 72:1215-1220.
13. Ben-Josef E, Shields AF, Vaishampayan U, Vaitkevicius V, El-Rayes BF,
McDermott P, Burmeister J, Bossenberger T, Philip PA: Intensity-modulated
radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.
Int J Radiat Oncol Biol Phys 2004, 59:454-459.
14. Yovino S, Poppe M, Jabbour S, David V, Garofalo M, Pandya N, Alexander R,
Hanna N, Regine WF: Intensity-modulated radiation therapy significantly
improves acute gastrointestinal toxicity in pancreatic and ampullary
cancers. Int J Radiat Oncol Biol Phys 2011, 79:158-162.
15. Milano MT, Chmura SJ, Garofalo MC, Rash C, Roeske JC, Connell PP,
Kwon OH, Jani AB, Heimann R: Intensity-modulated radiotherapy in
treatment of pancreatic and bile duct malignancies: toxicity and clinical
outcome. Int J Radiat Oncol Biol Phys 2004, 59:445-453.
16. Otto K: Volumetric modulated arc therapy: IMRT in a single gantry arc.
Med Phys 2008, 35:310-317.
17. Ling CC, Zhang P, Archambault Y, Bocanek J, Tang G, Losasso T:
Commissioning and quality assurance of RapidArc radiotherapy delivery
system. Int J Radiat Oncol Biol Phys 2008, 72:575-581.
18. Cozzi L, Dinshaw KA, Shrivastava SK, Mahantshetty U, Engineer R,
Deshpande DD, Jamema SV, Vanetti E, Clivio A, Nicolini G, Fogliata A: A
treatment planning study comparing volumetric arc modulation with
RapidArc and fixed field IMRT for cervix uteri radiotherapy. Radiother
Oncol 2008, 89:180-191.
19. Scorsetti M, Bignardi M, Clivio A, Cozzi L, Fogliata A, Lattuada P, Mancosu P,
Navarria P, Nicolini G, Urso G, et al: Volumetric modulation arc
radiotherapy compared with static gantry intensity-modulated
radiotherapy for malignant pleural mesothelioma tumor: a feasibility
study. Int J Radiat Oncol Biol Phy 2010, 77:942-949.
20. Vieillot S, Azria D, Lemanski C, Moscardo CL, Gourgou S, Dubois JB,
Aillères N, Fenoglietto P: Plan comparison of volumetric-modulated arc
therapy (RapidArc) and conventional intensity-modulated radiation
therapy (IMRT) in anal canal cancer. Radiat Oncol 2010, 5:92.
21. Eppinga W, Lagerwaard F, Verbakel W, Slotman B, Senan S: Volumetric
modulated arc therapy for advanced pancreatic cancer. Strahlenther
Onkol 2010, 186:382-387.
22. Dawson LA, Kavanagh BD, Paulino AC, Das SK, Miften M, Li XA, Pan C, Ten
Haken RK, Schultheiss TE: Radiation-associated kidney injury. Int J Radiat
Oncol Biol Phys 2010, 76:S108-115.
23. Cassady JR: Clinical radiation nephropathy. Int J Radiat Oncol Biol Phys
1995, 31:1249-1256.
24. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B,
Solin LJ, Wesson M: Tolerance of normal tissue to therapeutic irradiation.
Int J Radiat Oncol Biol Phys 1991, 21:109-122.
25. Devisetty K, Mell LK, Salama JK, Schomas DA, Miller RC, Jani AB, Roeske JC,
Aydogan B, Chmura SJ: A multi-institutional acute gastrointestinal toxicity
analysis of anal cancer patients treated with concurrent intensity-
modulated radiation therapy (IMRT) and chemotherapy. Radiother Oncol
2009, 93:298-301.
26. Kavanagh BD, Pan CC, Dawson LA, Das SK, Li XA, Ten Haken RK, Miften M:
Radiation dose-volume effects in the stomach and small bowel. Int J
Radiat Oncol Biol Phys 2010, 76:S101-107.
27. Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, Ten Haken RK:
Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 2010, 76:
S94-100.
28. Dorr W, Herrmann T: Second primary tumors after radiotherapy for
malignancies. Treatment-related parameters. Strahlenther Onkol 2002,
178:357-362.
29. Randall ME, Ibbott GS: Intensity-modulated radiation therapy for
gynecologic cancers: pitfalls, hazards, and cautions to be considered.
Semin Radiat Oncol 2006, 16:138-143.
doi:10.1186/1748-717X-6-147
Cite this article as: Vieillot et al.: Bilateral kidney preservation by
volumetric-modulated arc therapy (RapidArc) compared to conventional
radiation therapy (3D-CRT) in pancreatic and bile duct malignancies.
Radiation Oncology 2011 6:147.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Vieillot et al. Radiation Oncology 2011, 6:147
http://www.ro-journal.com/content/6/1/147
Page 8 of 8
